Xenetic Biosciences, Inc.
10-K
March 12, 2026
Key Highlights
- Advancing lead DNase technology into Phase 1/2a clinical trials for pancreatic c...
- Proprietary PolyXenยฎ platform offers drug delivery improvements and is actively ...
- A comprehensive strategic review is underway by the Board of Directors to evalua...
Read Analysis
๐ค AI Generated